AT406 (SM-406) is primarily used in research and development as a potent inhibitor of IAP (Inhibitor of Apoptosis Proteins). Its application is focused on studying cancer therapies, particularly in targeting cancer cells that evade apoptosis. By inhibiting IAPs, it promotes programmed cell death in malignant cells, making it a promising candidate for preclinical studies in oncology. Researchers utilize it to explore its potential in enhancing the effectiveness of chemotherapy and radiotherapy, as well as in overcoming drug resistance in various cancer types. Additionally, it is investigated for its role in combination therapies to improve treatment outcomes in aggressive cancers.